Micofenolat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil acts as an antimetabolite immunosuppressant in several transplant‑related and autoimmune conditions.

• Organ transplant rejection (kidney, heart, liver): helps prevent acute and chronic rejection by suppressing lymphocyte proliferation.
• Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
• Graft‑versus‑host disease: lowers the incidence and severity of GVHD after hematopoietic stem‑cell transplantation.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo guanosine nucleotide synthesis in activated T and B lymphocytes, leading to reduced proliferation and diminished immune responses, while sparing other cell types that can use salvage pathways.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: frequent loose stools.
• Headache: transient cranial pain.
• Abdominal pain: discomfort in the stomach area.
• Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects

• Leukopenia: significant drop in white blood cells.
• Anemia: reduced red blood cell count.
• Severe infections: opportunistic or bacterial infections.
• Elevated liver enzymes: signs of hepatic stress.
• Malignancy risk: potential increased cancer incidence.
• Progressive multifocal leukoencephalopathy (PML): rare viral brain infection.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

• Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
• Monitor liver function: check transaminases periodically.
• Avoid use in pregnancy: drug is contraindicated due to teratogenic risk.
• Assess renal function: dose adjustments may be needed in impairment.
• Review concomitant nephrotoxic drugs: avoid additive kidney injury.
• Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil interacts with several agents that can alter its safety or efficacy.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression.
• Live vaccines: heightened risk of infection.
• Cholestyramine: reduces oral absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely)

• Cyclosporine or tacrolimus: may increase mycophenolate exposure.
• NSAIDs: can exacerbate renal toxicity when combined.